United States Patent 6,258,830: Claim Scope, Patent Expiration, Orange Book Status, and Tazarotene Generic Risk

U.S. Patent No. 6,258,830 protects a narrow topical gel formulation containing tazarotene, Polysorbate 40, Poloxamer 407, and approximately 2% hexylene glycol. The patent does not broadly protect tazarotene, all tazarotene gels, or every formulation for acne or psoriasis. Its commercial value was concentrated in the specified excipient system and its release and solubility characteristics.

The patent term has expired. Based on the U.S. filing date and the statutory patent term applicable to the patent, the expected expiration date was December 7, 2018, subject to any patent-term adjustment. The claims therefore do not present a current U.S. blocking patent against generic tazarotene products.

What does U.S. Patent 6,258,830 protect?

The patent covers a stable topical gel containing four principal elements:

Required element	Claim 1	Claim 2
Synthetic retinoid identified as tazarotene	Yes	Yes
Polysorbate 40	Greater than 0% to about 0.4 wt%	Greater than 0% to about 0.4 wt%
Poloxamer 407	Greater than 0% to about 0.4 wt%	Greater than 0%, with no express upper limit
Hexylene glycol	About 2 wt%	About 2 wt%
Gel formulation	Yes	Yes
Treatment of acne and psoriasis	Yes	Yes
Functional formulation objective	Control release to skin	Control solubility
Stability requirement	Yes	Yes

The patent is best characterized as a formulation patent directed to a controlled-delivery tazarotene gel. It is narrower than a compound patent and narrower than a generic claim to a topical retinoid composition.

The active ingredient is conventionally identified as tazarotene, whose chemical name is ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate. The chemical name in the supplied claim text appears to omit “ethynyl” and contains a bracket mismatch. That textual issue should be checked against the issued patent and certified patent file. The analysis below assumes the claimed retinoid is tazarotene.

How should claim 1 be construed?

Claim 1 requires the following combination:

A stable gel.
An effective amount of tazarotene.
Polysorbate 40 in an amount greater than 0% and up to approximately 0.4 wt%.
Poloxamer 407 in an amount greater than 0% and up to approximately 0.4 wt%.
Hexylene glycol at approximately 2 wt%.
A formulation in which the excipients control release of tazarotene to the skin.
A formulation intended for treatment of both acne and psoriasis.

The numerical limitations are central. A formulation containing 0.1% Polysorbate 40, 0.2% Poloxamer 407, and 2% hexylene glycol would fall within the stated numerical ranges, assuming the other limitations were met.

A formulation containing no Poloxamer 407 would not literally satisfy claim 1 because the claim requires Poloxamer 407 at greater than 0%. The phrase in the final clause stating that Poloxamer 407 is “optionally” present conflicts with the earlier mandatory composition limitation. The earlier express amount limitation would ordinarily control over a later inconsistent reference, but the final interpretation would depend on the issued claim language, prosecution history, and any correction or amendment made during examination.

The phrase “about 2 wt%” creates a numerical tolerance rather than an unlimited range. Courts generally interpret “about” in view of the specification, examples, analytical precision, prosecution history, and the technical meaning of the term in the relevant field. A formulation with 1.5% or 3.0% hexylene glycol cannot be assumed to fall within the claim merely because it is chemically similar.

How should claim 2 be construed?

Claim 2 is similar to claim 1 but differs in two important respects.

First, it requires Poloxamer 407 at greater than 0% without an express upper limit. This is potentially broader than claim 1 with respect to the Poloxamer 407 concentration. The limitation remains subject to the other claim requirements, including the Polysorbate 40 range, approximately 2% hexylene glycol, a stable gel, and tazarotene.

Second, claim 2 describes the formulation as controlling the “solubility” of tazarotene rather than controlling its “release” to the skin. This change may affect claim scope. A formulation can improve solubility without producing a particular release profile, and a formulation can control release through mechanisms that do not materially alter equilibrium solubility.

The phrase “optionally Poloxamer 407” is internally inconsistent with the requirement that Poloxamer 407 be present at greater than 0%. If the issued patent contains this language, claim construction would likely focus on whether “optionally” modifies the excipient’s functional role rather than its physical presence. A court could also treat the inconsistency as an ambiguity requiring reference to the specification and prosecution record.

What formulations are protected by U.S. Patent 6,258,830?

The protected formulation class is defined by the combination of active ingredient, excipients, concentration ranges, dosage form, and functional performance.

Likely within the literal scope

A tazarotene gel containing:

more than 0% and no more than approximately 0.4% Polysorbate 40;
more than 0% and no more than approximately 0.4% Poloxamer 407;
approximately 2% hexylene glycol; and
a stable gel that controls tazarotene release or solubility.

The formulation would also need to satisfy the intended treatment limitations for acne and psoriasis if those limitations are treated as legally operative.

Likely outside the literal scope

A product may fall outside the literal language if it:

replaces Polysorbate 40 with another surfactant;
omits Poloxamer 407, subject to the claim inconsistency;
uses hexylene glycol at a concentration materially outside the “about 2 wt%” range;
uses a cream, lotion, ointment, foam, solution, or suspension rather than a gel;
uses a retinoid other than tazarotene;
contains the listed ingredients but does not satisfy the stability or functional release or solubility limitation.

A formulation outside the literal language could still raise a doctrine-of-equivalents issue, but the risk would depend on prosecution history and whether the substituted excipient or concentration performs substantially the same function in substantially the same way with substantially the same result. Because the patent has expired, this issue is primarily historical rather than a current enforcement concern.

How strong was the patent estate for tazarotene?

The patent estate had several distinct layers:

Patent layer	Subject matter	Current U.S. status
Compound protection	Tazarotene and related retinoids	Expired
Method-of-use protection	Treatment of dermatological disorders	Expired or no longer blocking, depending on patent
Formulation protection	Tazarotene gel with specified excipients	U.S. Patent 6,258,830 expired
Regulatory exclusivity	NDA-based FDA exclusivity	Expired
Manufacturing protection	Potential process, impurity, or scale-up claims	Requires separate patent-family review

U.S. Patent 6,258,830 was a formulation patent rather than the foundational tazarotene compound patent. Its commercial function was to delay or complicate substitution with a particular gel formulation after basic compound protection had ended.

The estate was stronger against a product designed to replicate the branded formulation than against a generic manufacturer using a different vehicle, surfactant, solubilizer, or release system. A generic could seek approval for a formulation that was pharmaceutically equivalent or therapeutically comparable without reproducing every excipient limitation in the patent.

When did U.S. Patent 6,258,830 lose exclusivity?

The patent term expired in approximately December 2018, calculated from the U.S. nonprovisional filing date under the 20-year patent term applicable to modern U.S. applications. The patent was issued on July 24, 2001, but the issue date does not establish the expiration date for a patent governed by the 20-year term.

Event	Date or period
U.S. nonprovisional filing	December 7, 1998
Patent issued	July 24, 2001
Expected ordinary expiration	December 7, 2018
Current enforceability	Expired

Any patent-term adjustment would have to be added to the ordinary expiration date. The patent should not be treated as currently enforceable based solely on the patent number or its historical Orange Book listing.

What was the Orange Book status of the tazarotene formulation?

Tazarotene was approved by the FDA as a topical retinoid for dermatological indications, including acne and plaque psoriasis. Tazorac products included gel and cream dosage forms. The FDA Orange Book historically listed patents associated with approved tazarotene products, including formulation patents relevant to the gel product. The Orange Book is the principal FDA source for listed patents and regulatory exclusivity associated with approved small-molecule drugs (U.S. Food and Drug Administration, n.d.-a).

The Orange Book listing of a patent does not establish that every claim is valid or infringed. It identifies patents that the NDA holder represented as covering the approved drug or an approved method of use. Once the listed patent expired, the listing no longer created a live patent barrier to an ANDA applicant.

Tazarotene is a small molecule, not a biologic. Biosimilar provisions under the Public Health Service Act are therefore irrelevant. Competition proceeds through the ANDA pathway rather than the abbreviated biologics license application pathway.

Were there Paragraph IV challenges to this patent?

A Paragraph IV certification is an ANDA applicant’s assertion that a listed patent is invalid, unenforceable, or not infringed. A Paragraph IV certification concerning U.S. Patent 6,258,830 could have triggered patent litigation under the Hatch-Waxman framework before the patent expired.

The supplied record does not identify a specific ANDA sponsor, notice letter, district-court complaint, settlement agreement, or litigation docket directed to this patent. Because the patent expired in 2018, a new Paragraph IV challenge to this patent would not create a current launch barrier. Any historical challenge would have had commercial significance only during the remaining patent term.

The existence of generic tazarotene approvals does not, by itself, establish that a particular generic applicant defeated this patent through litigation. Approval could also have followed a Paragraph III certification, a non-infringement position, a settlement, patent expiration, or a formulation that did not implicate the asserted claims.

Which companies challenged tazarotene exclusivity?

Public regulatory and litigation analysis must distinguish among:

the NDA holder and branded manufacturer;
ANDA sponsors;
suppliers of active pharmaceutical ingredient;
authorized generic distributors; and
defendants in patent litigation.

The supplied materials do not identify a company that challenged U.S. Patent 6,258,830 through a documented Paragraph IV notice or lawsuit. Generic tazarotene products have entered the U.S. market, but the product-level existence of generic competition does not establish the identity or legal strategy of the first challenger.

The practical competitive field has included generic manufacturers offering tazarotene gel and cream products in concentrations corresponding to approved branded products. These products compete primarily through price, payer coverage, pharmacy substitution, supply reliability, and formulation performance.

What generic entry risks existed before expiration?

Before December 2018, a generic sponsor faced several possible risks:

Risk	Relevance
Literal infringement	Highest if the generic copied the claimed excipient ranges
Doctrine of equivalents	Possible for substituted excipients or near-boundary concentrations
Regulatory delay	Possible through a 30-month stay after patent litigation
Product differentiation	Required to avoid the narrow formulation limitations
Stability and release testing	Needed to support formulation equivalence and commercial performance
Method-of-use exposure	Relevant if labeling retained patented indications
Supply risk	Relevant if the formulation depended on specialized excipient sourcing

The narrow composition limits gave a generic manufacturer room to design around the patent. Examples include changing the surfactant, changing the polymer, using a different solubilizer, or selecting a vehicle that did not include approximately 2% hexylene glycol. Each design-around would still require FDA-compliant product development and an adequate basis for demonstrating pharmaceutical equivalence or therapeutic equivalence.

What manufacturing and formulation barriers did the patent create?

The patent did not claim a manufacturing process in the supplied claims. Its barrier was formulation-specific. The technical challenge was to maintain a stable tazarotene gel while controlling solubility and delivery to the skin.

Tazarotene is poorly water-soluble and sensitive to formulation conditions. Surfactants and polymeric solubilizers can affect:

drug crystallization;
viscosity;
uniformity;
skin penetration;
release rate;
physical stability;
preservative performance; and
patient tolerability.

A generic manufacturer could avoid the patent but still encounter development barriers. A different excipient system might alter drug availability, spreadability, drying time, irritation, or bioequivalence risk. Those technical constraints are separate from the legal scope of Patent 6,258,830.

How does Patent 6,258,830 compare with a compound patent?

A compound patent generally protects the chemical entity itself and can block use across multiple dosage forms and indications. Patent 6,258,830 protected a specific delivery system.

Issue	Compound patent	U.S. Patent 6,258,830
Primary subject	Tazarotene molecule	Tazarotene topical gel
Breadth	Broad across formulations	Narrow formulation combination
Design-around difficulty	High before expiration	Moderate to high
Dependence on excipients	No	Yes
Relevance to creams or foams	Potentially broad	Generally limited
Current status	Expired	Expired
Biosimilar relevance	None	None

The formulation patent could extend practical market protection after compound protection ended, but it could not prevent all tazarotene products from entering the market.

Key Takeaways

U.S. Patent 6,258,830 claims a narrow tazarotene gel formulation.
The key excipients are Polysorbate 40, Poloxamer 407, and approximately 2% hexylene glycol.
Claim 1 requires Poloxamer 407 at more than 0% and up to approximately 0.4%.
Claim 2 requires Poloxamer 407 at more than 0% but contains an apparent inconsistency because it also describes the ingredient as optional.
The patent does not broadly cover tazarotene, every tazarotene gel, or all acne and psoriasis treatments.
The expected U.S. expiration date was December 7, 2018, subject to any patent-term adjustment.
The patent is expired and does not present a current U.S. enforcement barrier.
Tazarotene is a small molecule, so biosimilar analysis does not apply.
Generic competition can avoid the historical claim scope through changes to excipients, concentrations, dosage form, or release system.
The supplied record does not identify a specific Paragraph IV challenger, litigation settlement, or company that litigated this patent.

FAQs

Does U.S. Patent 6,258,830 cover all Tazorac products?

No. The claims are directed to a specific stable tazarotene gel with defined excipients and concentration ranges. Products using materially different vehicles or excipient systems may fall outside the claims.

Can a generic tazarotene product omit Poloxamer 407?

A product omitting Poloxamer 407 would not literally satisfy the express Poloxamer limitation in claim 1. Claim 2 contains conflicting language and requires review of the issued claim and prosecution history.

Is hexylene glycol at exactly 2% required?

The claims use “about 2 wt%,” not an exact 2.000% requirement. The legally relevant range depends on the specification, technical context, prosecution history, and accepted measurement tolerance.

Does the patent cover a tazarotene cream?

The supplied claims require a gel. A cream would not literally satisfy the dosage-form limitation unless the product were legally characterized as a gel despite its commercial designation.

Can this expired patent block a new U.S. generic launch?

No. An expired patent cannot ordinarily support a current injunction against a product that would otherwise satisfy FDA requirements. Historical litigation or settlement terms could affect specific contractual rights, but the patent itself is no longer an enforceable exclusion right.

References

United States Patent and Trademark Office. (2001). U.S. Patent No. 6,258,830, topical formulations containing tazarotene.
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.-b). Tazorac (tazarotene) prescribing information.
U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs.
Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. §§ 355, 360cc; 35 U.S.C. §§ 154, 156.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	215836	⤷ Start Trial
Austria	336263	⤷ Start Trial
Australia	2821895	⤷ Start Trial
Australia	693905	⤷ Start Trial
Canada	2191773	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,258,830

Summary for Patent: 6,258,830